Human Papillomavirus Vaccination Prevalence and Disproportionate Cancer Burden Among US Veterans
Menée aux Etats-Unis, cette étude estime la prévalence de la vaccination contre le papillomavirus humain (HPV) chez les anciens combattants et évalue, au sein de cette population, le risque de cancer lié au HPV et la mortalité
In the US, over 45 000 cases of human papillomavirus (HPV)–associated malignant neoplasms are diagnosed annually. The Advisory Committee on Immunization Practices recommends HPV vaccination until age 26 years to prevent HPV-associated malignant neoplasms in males and females. Active-duty military service members and veterans are twice as likely as the general population to develop oncogenic HPV infections, resulting in a higher risk of HPV-associated cancers and mortality, and HPV-associated oropharyngeal cancer, which occurs predominantly in males, is rising more rapidly among veterans than civilians. There are no universal HPV vaccination requirements or campaigns targeted at service members or veterans. In this study, we provide, to our knowledge, the first national estimate of HPV vaccination prevalence among eligible veterans.
JAMA Oncology 2023